Skip to main content

Invitrogen: Nov 20, 2008

Invitrogen has introduced the Invivofectamine delivery reagent for the delivery of siRNAs in vivo.
According to the company, the reagent can be injected in small volumes and without high pressure, and provides extra stability to siRNA so the oligo will arrive at its target intact. The reagent is non-viral and has minimal toxicity, the company added.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.